Abstract
Objective Magnetic resonance imaging (MRI) has shown that estimated brain age is deviant from chronological age in various common brain disorders. Brain age estimation could be useful for investigating patterns of brain maturation and integrity, aiding to elucidate brain mechanisms underlying these heterogeneous conditions. Here, we examined functional brain age in two large samples of children and adolescents and its relation to mental health.
Methods We used resting-state fMRI data from the Philadelphia Neurodevelopmental Cohort (PNC; n=1126, age range 8-22 years) to estimate functional connectivity between brain networks, and utilized these as features for brain age prediction. We applied the prediction model to 1387 individuals (age range 8-22 years) in the Healthy Brain Network sample (HBN). In addition, we estimated brain age in PNC using a cross-validation framework. Next, we tested for associations between brain age gap and various aspects of psychopathology and cognitive performance.
Results Our model was able to predict age in the independent test samples, with a model performance of r=0.54 for the HBN test set, supporting consistency in functional connectivity patterns between samples and scanners. Linear models revealed a significant association between brain age gap and psychopathology in PNC, where individuals with a lower estimated brain age, had a higher overall symptom burden. These associations were not replicated in HBN.
Discussion Our findings support the use of brain age prediction from fMRI-based connectivity. While requiring further extensions and validations, the approach may be instrumental for detecting brain phenotypes related to intrinsic connectivity and could assist in characterizing risk in non-typically developing populations.
Competing Interest Statement
OAA is a consultant for HealthLytix.
Funding Statement
The authors were funded by the Research Council of Norway #276082 (LifespanHealth), #223273 (NORMENT), #249795, #298646, #300767, #283798; H2020 European Research Council #802998 (BRAINMINT); The South-East Norway Regional Health Authority #2019101, #2019107, #2020086; the Swiss National Science Foundation #PZ00P3_193658.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
HBN sample: The Chesapeake Institutional Review Board approved the study (https://www. chesapeakeirb.com/). PNC sample: The University of Pennsylvania and CHOP Institutional Review Boards approved the study (Satterthwaite et al., 2016).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data incorporated in this work were gathered from the open access Healthy Brain Network and The Philadelphia Neurodevelopmental Cohort resource.
http://www.healthybrainnetwork.org
https://www.med.upenn.edu/bbl/philadelphianeurodevelopmentalcohort.html
